1
Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Condition(s):ER-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:January 18, 2023Recruiting
Fulvestrant: 451 Clinical Trials, Page 1 of 46
Hide Studies Not Open or Pending
2
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Condition(s):Breast CancerLast Updated:May 14, 2021Completed
3
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Condition(s):PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid TumorLast Updated:November 21, 2022Recruiting
4
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Condition(s):Breast CancerLast Updated:January 6, 2022Not yet recruiting
5
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Condition(s):Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Breast; Cancer of Breast; Malignant Tumor of Breast; Breast TumorLast Updated:August 5, 2022Withdrawn
6
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Condition(s):Locally Advanced or Metastatic Breast CancerLast Updated:June 13, 2022Recruiting
7
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Condition(s):Advanced Breast CancerLast Updated:November 28, 2022Recruiting
8
Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.
Condition(s):Postmenopausal Women With ER+ HER2- Primary Breast CancerLast Updated:February 6, 2020Completed
9
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Condition(s):Breast CancerLast Updated:November 30, 2020Recruiting
10
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
Condition(s):ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic CancerLast Updated:January 26, 2023Recruiting